US equities
|
NVDA
$173.73
▲+2.87%
MU
$811.30
▲+11.89%
AMD
$552.90
▲+7.32%
SNDK
$977.69
▲+13.69%
SPCX
$139.75
▼-2.33%
MSFT
$521.12
▼-2.26%
AAPL
$355.63
▲+2.04%
AVGO
$345.22
▲+3.99%
NVDA
$173.73
▲+2.87%
MU
$811.30
▲+11.89%
AMD
$552.90
▲+7.32%
SNDK
$977.69
▲+13.69%
SPCX
$139.75
▼-2.33%
MSFT
$521.12
▼-2.26%
AAPL
$355.63
▲+2.04%
AVGO
$345.22
▲+3.99%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
DiaMedica Therapeutics Inc. - Common Stock
(NQ:
DMAC
)
9.660
-0.010 (-0.10%)
Delayed Quote
Updated: 4:00 PM EST, Nov 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about DiaMedica Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026
November 05, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
October 22, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
October 19, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
September 30, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics (NASDAQ:DMAC) Posts Wider Q1 Loss but Clinical Catalysts Fuel Stock Resilience
↗
May 06, 2026
Via
Chartmill
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
September 02, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript
↗
August 17, 2026
ReMEDy2 stroke trial nears interim analysis with 85% enrollment complete.
Via
The Motley Fool
Topics
Earnings
DiaMedica Therapeutics Q2 Earnings Call Highlights
↗
August 11, 2026
DiaMedica Therapeutics (NASDAQ:DMAC) said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the...
Via
MarketBeat
Topics
Earnings
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 10, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
August 04, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
June 23, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
June 16, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica (DMAC) Q4 2025 Earnings Transcript
↗
June 01, 2026
DiaMedica (DMAC) Q4 2025 Earnings Transcript
Via
The Motley Fool
Topics
Intellectual Property
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
May 27, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
May 20, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
May 12, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica (DMAC) Q1 2026 Earnings Transcript
↗
May 08, 2026
DiaMedica (DMAC) Q1 2026 Earnings Transcript
Via
The Motley Fool
Topics
Death
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
May 06, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
April 30, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
RedChip's Biotech Virtual Investor Conference Replays Now Available
April 21, 2026
Via
ACCESS Newswire
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
April 07, 2026
Via
ACCESS Newswire
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
March 30, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings
↗
March 30, 2026
DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.
Via
Benzinga
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
March 23, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
March 05, 2026
From
DiaMedica Therapeutics Inc
Via
Business Wire
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
February 24, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
December 18, 2025
From
DiaMedica Therapeutics Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
November 14, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
